论文部分内容阅读
目的探讨尤瑞克林联合奥扎格雷钠治疗急性脑梗死的临床疗效。方法将170例急性脑梗死患者随机分为对照组和治疗组,各85例,对照组给予奥扎格雷钠治疗,治疗组给予尤瑞克林联合奥扎格雷钠治疗。观察两组患者临床疗效、美国国立卫生研究院卒中量表评分(HINSS)、梗死体积、血液流变学指标及不良反应情况。结果两组患者性别、年龄、伴发病及病发部位等一般资料无显著性差异(P>0.05),具有可比性。治疗组疗效显著优于对照组(Z=-2.28,P=0.02);NIHSS评分方面,对照组治疗前后分别为23.38±3.24 vs 12.22±7.17,治疗组为23.18±2.96 vs 9.16±6.95,治疗组治疗后效果优于对照组(t=2.83,P<0.05);梗死体积方面,对照组治疗前后分别为5.99±0.60 vs 5.00±0.34,治疗组为5.99±0.62 vs 4.00±0.21,治疗组治疗后效果优于对照组(t=23.11,P<0.05);血液流变学各项指标,治疗组纤维蛋白原、血浆黏度、全血低切黏度和全血高切黏度改善程度均优于对照组(t值分别为14.67,7.35,19.70和5.33,P<0.05);两组不良反应发生情况无明显差异。结论尤瑞克林联合奥扎格雷钠可有效治疗急性脑梗死,在扩血管、抗凝的基础上修复受损神经元,改善患者预后,且无明显严重不良反应,值得临床推广。
Objective To investigate the clinical efficacy of uracil combined with ozagrel sodium in the treatment of acute cerebral infarction. Methods A total of 170 patients with acute cerebral infarction were randomly divided into control group and treatment group, 85 cases in each group. Ozagrel sodium was given to the control group and urethrin plus ozagrel sodium was given to the treatment group. The clinical efficacy, the National Institutes of Health Stroke Scale score (HINSS), infarct volume, hemorheological parameters and adverse reactions were observed. Results There was no significant difference (P> 0.05) between the two groups in general information such as sex, age, companion disease and disease site, which were comparable. The therapeutic effect in the treatment group was significantly better than that in the control group (Z = -2.28, P = 0.02). In the NIHSS score, the control group was 23.38 ± 3.24 vs 12.22 ± 7.17 before and after treatment, 23.18 ± 2.96 vs 9.16 ± 6.95 in the treatment group Compared with the control group (t = 2.83, P <0.05), the infarction volume of the control group before and after treatment was 5.99 ± 0.60 vs 5.00 ± 0.34, and the treatment group was 5.99 ± 0.62 vs 4.00 ± 0.21 (T = 23.11, P <0.05). The indexes of hemorheology, fibrinogen, plasma viscosity, whole blood low shear viscosity and whole blood high shear viscosity in the treatment group were all better than those in the control group (t = 14.67, 7.35, 19.70 and 5.33 respectively, P <0.05). There was no significant difference between the two groups in adverse reactions. Conclusion The combination of ralciclovir and ozagrel sodium can effectively treat acute cerebral infarction and repair damaged neurons on the basis of vasodilator and anticoagulation to improve the prognosis of patients with no serious adverse reactions and is worthy of clinical promotion.